• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, May 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Red Sea fungus yields leads for new epilepsy drugs

Bioengineer by Bioengineer
May 9, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New treatments for epilepsy are sorely needed because current medications don't work for many people with the disease. To find new leads, researchers have now turned to the sea — a source of unique natural products that have been largely untapped for prospective drugs. The scientists report in the journal ACS Chemical Neuroscience that two metabolites produced by a fungus from the Red Sea look promising.

The term "epilepsy" covers a spectrum of brain disorders with symptoms ranging from mildly odd sensations to seizures, loss of consciousness and death. Worldwide, the condition affects 50 million people, according to the World Health Organization. Current treatments work in only about 70 percent of those who try them. To identify some new options, Marcel Jaspars, Peter A. M. de Witte and colleagues teamed up in an international collaboration called the EU PharmSea project that aimed to discover novel compounds from marine microorganisms in some of the deepest, coldest and hottest places on Earth.

According to the researchers, this study was the first-ever systematic large-scale screen of marine-derived natural products for potential anti-seizure drugs. Initial tests of a variety of these compounds revealed that two γ-lactams produced by the Red Sea fungus Aspergillus fumigatus reduced the number and length of seizures in zebrafish, a model organism they used for high-volume screening of compounds. The researchers then showed that these natural substances, known as pseurotin A2 and azaspirofuran A, also shortened seizures in a mouse model of epilepsy. The scientists recommend further investigation of these metabolites to explore their biomolecular targets and to design more potent analogs.

###

The research was supported by the PharmaSea project, funded by the European Union's Seventh Framework Programme.

The abstract that accompanies this study is available here.

The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact [email protected].

Follow us on Twitter | Facebook

Media Contact

Katie Cottingham
[email protected]
301-775-8455
@ACSpressroom

http://www.acs.org

Share12Tweet7Share2ShareShareShare1

Related Posts

Nonlinear Atomic Tunneling Enhanced by Bright Squeezed Vacuum

May 21, 2026

Genetic Insights from 619,372 Metabolic Profiles

May 21, 2026

Bacterial STIs Hit Record Levels in Europe as Congenital Syphilis Cases Nearly Double

May 21, 2026

Oral Semaglutide Lowers Cardiometabolic Risks in Obesity

May 21, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    New Study Reveals Plants Can Detect the Sound of Rain

    733 shares
    Share 292 Tweet 183
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    304 shares
    Share 122 Tweet 76
  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    846 shares
    Share 338 Tweet 212
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Innovative Reusable Brick Walls Revolutionize Construction Industry

Nonlinear Atomic Tunneling Enhanced by Bright Squeezed Vacuum

Label-Free Super-Resolution Imaging of Live Cells

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.